<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>neurocare America | News &amp; Insights on Apollo TMS Therapy</title>
    <link>https://www.neurocaregroup.com/en-us/news-insights</link>
    <description>Latest news and insights from neurocare group America, bringing leading neuromodulation technology to the US.</description>
    <language>en-us</language>
    <pubDate>Wed, 18 Nov 2026 18:34:18 GMT</pubDate>
    <dc:date>2026-11-18T18:34:18Z</dc:date>
    <dc:language>en-us</dc:language>
    <item>
      <title>neurocare and Wave Neuroscience partner to expand patient access to FDA-Cleared MeRT® therapy for PTSD on the Apollo TMS Therapy System</title>
      <link>https://www.neurocaregroup.com/en-us/news-insights/neurocare-and-wave-neuroscience-partner-to-expand-patient-access-to-fda-cleared-mert-therapy-for-ptsd-on-the-apollo-tms-therapy-system-1</link>
      <description>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-and-wave-neuroscience-partner-to-expand-patient-access-to-fda-cleared-mert-therapy-for-ptsd-on-the-apollo-tms-therapy-system-1" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/neurocare-apollo-tms-ocd-coil-placement-treatment-2.jpg" alt="neurocare and Wave Neuroscience partner to expand patient access to FDA-Cleared MeRT® therapy for PTSD on the Apollo TMS Therapy System" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;span style="color: #000000;"&gt;Munich, Germany and Alpharetta, GA, United States, September 25, 2026&lt;/span&gt;&amp;nbsp;- neurocare group AG (“neurocare” or the “Company”), a best practice platform for mental health and performance, and the company behind the neurocare Apollo TMS platform, today announced a strategic collaboration with Wave Neuroscience, expanding access to complementary neuromodulation solutions and supporting broader availability of Wave Neuroscience's FDA-cleared MeRT® system to improve the lives of patients suffering from PTSD. About 6% of the US population, or 16 million, will experience PTSD symptoms in their lifetime, and about 27% of these will attempt suicide.&lt;/p&gt;</description>
      <content:encoded>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-and-wave-neuroscience-partner-to-expand-patient-access-to-fda-cleared-mert-therapy-for-ptsd-on-the-apollo-tms-therapy-system-1" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/neurocare-apollo-tms-ocd-coil-placement-treatment-2.jpg" alt="neurocare and Wave Neuroscience partner to expand patient access to FDA-Cleared MeRT® therapy for PTSD on the Apollo TMS Therapy System" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;span style="color: #000000;"&gt;Munich, Germany and Alpharetta, GA, United States, September 25, 2026&lt;/span&gt;&amp;nbsp;- neurocare group AG (“neurocare” or the “Company”), a best practice platform for mental health and performance, and the company behind the neurocare Apollo TMS platform, today announced a strategic collaboration with Wave Neuroscience, expanding access to complementary neuromodulation solutions and supporting broader availability of Wave Neuroscience's FDA-cleared MeRT® system to improve the lives of patients suffering from PTSD. About 6% of the US population, or 16 million, will experience PTSD symptoms in their lifetime, and about 27% of these will attempt suicide.&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=6673911&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fwww.neurocaregroup.com%2Fen-us%2Fnews-insights%2Fneurocare-and-wave-neuroscience-partner-to-expand-patient-access-to-fda-cleared-mert-therapy-for-ptsd-on-the-apollo-tms-therapy-system-1&amp;amp;bu=https%253A%252F%252Fwww.neurocaregroup.com%252Fen-us%252Fnews-insights&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <category>PTSD</category>
      <category>Press Release</category>
      <category>TMS</category>
      <category>FDA</category>
      <pubDate>Thu, 24 Sep 2026 22:30:00 GMT</pubDate>
      <guid>https://www.neurocaregroup.com/en-us/news-insights/neurocare-and-wave-neuroscience-partner-to-expand-patient-access-to-fda-cleared-mert-therapy-for-ptsd-on-the-apollo-tms-therapy-system-1</guid>
      <dc:date>2026-09-24T22:30:00Z</dc:date>
      <dc:creator>neurocare group</dc:creator>
    </item>
    <item>
      <title>neurocare group's Apollo TMS Therapy Devices Now Have FDA Clearance to Treat Adolescents Suffering With Major Depression</title>
      <link>https://www.neurocaregroup.com/en-us/news-insights/neurocare-groups-apollo-tms-therapy-devices-now-have-fda-clearance-to-treat-adolescents-suffering-with-major-depression</link>
      <description>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-groups-apollo-tms-therapy-devices-now-have-fda-clearance-to-treat-adolescents-suffering-with-major-depression" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/Resources%20-%20Downloads%20-%20Sales/Apollo%20Images/neurocare-TMS2818_Patient-Apollo-TMS-Coil.jpg" alt="neurocare group's Apollo TMS Therapy Devices Now Have FDA Clearance to Treat Adolescents Suffering With Major Depression" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;span&gt;Munich, Germany; Atlanta, Georgia, September 10, 2025 – neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance, today announced it has recei&lt;/span&gt;&lt;span&gt;ved FDA clearance for the treatment of &lt;/span&gt;&lt;i&gt;&lt;span&gt;Major Depressive Disorder&lt;/span&gt;&lt;/i&gt;&lt;span&gt; (MDD) in adolescents using its Apollo TMS Therapy devices, a state-of-the-art Transcranial Magnetic Stimulation (TMS) system.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;Major depression affects an estimated 5 million adolescents in the U.S. each year, yet treatment options remain limited. Currently, only two oral antidepressants are FDA-approved for use in this age group, and both carry a “black box” warning—the strongest warning the FDA issues for medications—due to an increased risk of suicidal thoughts and actions. These medications have an effectiveness rate of only about 35% in achieving remission, and many patients discontinue due to side effects or lack of clinical benefit.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;TMS offers a safe, non-invasive, and drug-free alternative, with no black box warning and no medication-related side effects. Clinical studies show that approximately 60% of patients achieve remission with TMS, making it a promising new treatment option for adolescents who have not found success with other treatments.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;During TMS Therapy, clinicians position a magnetic coil on the patient’s head to deliver targeted stimulation to specific brain regions involved in mood regulation. neurocare’s engineering team in Germany has developed advanced technology where the magnetic field is more efficient at providing the prescribed stimulation. This advancement improves the impact of treatment, giving patients the best possible chance to benefit from their psychiatrist’s prescribed therapy.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;“Our mission has always been to expand access to safe and effective treatments for those who need them most,” said Stanford Miller, Managing Director of neurocare group’s North American operations. “This clearance allows providers to offer adolescents a proven therapy without the risks and limitations of medication, giving hope to families searching for better treatment options.”&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;br&gt;&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;br&gt;&lt;/span&gt;&lt;span&gt;Since 2021, neurocare has installed more than 300 Apollo systems in clinics and major institutions across the U.S., helping with the treatment of complex cases of Major Depressive Disorder (MDD) in adults, as well as Obsessive Compulsive Disorder (OCD). The Apollo TMS Therapy product line is FDA-cleared for the treatment of MDD in adult patients who have not had an adequate response to oral antidepressants. It is also FDA-cleared as an adjunctive treatment for OCD in adult patients who have not responded to traditional therapies. The same advanced technology is now FDA-cleared as an adjunctive treatment for adolescents with MDD. Most private and public insurers cover TMS Therapy for adults with MDD, and an increasing number are extending coverage to adolescents.&lt;/span&gt;&lt;/p&gt;</description>
      <content:encoded>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-groups-apollo-tms-therapy-devices-now-have-fda-clearance-to-treat-adolescents-suffering-with-major-depression" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/Resources%20-%20Downloads%20-%20Sales/Apollo%20Images/neurocare-TMS2818_Patient-Apollo-TMS-Coil.jpg" alt="neurocare group's Apollo TMS Therapy Devices Now Have FDA Clearance to Treat Adolescents Suffering With Major Depression" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;span&gt;Munich, Germany; Atlanta, Georgia, September 10, 2025 – neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance, today announced it has recei&lt;/span&gt;&lt;span&gt;ved FDA clearance for the treatment of &lt;/span&gt;&lt;i&gt;&lt;span&gt;Major Depressive Disorder&lt;/span&gt;&lt;/i&gt;&lt;span&gt; (MDD) in adolescents using its Apollo TMS Therapy devices, a state-of-the-art Transcranial Magnetic Stimulation (TMS) system.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;Major depression affects an estimated 5 million adolescents in the U.S. each year, yet treatment options remain limited. Currently, only two oral antidepressants are FDA-approved for use in this age group, and both carry a “black box” warning—the strongest warning the FDA issues for medications—due to an increased risk of suicidal thoughts and actions. These medications have an effectiveness rate of only about 35% in achieving remission, and many patients discontinue due to side effects or lack of clinical benefit.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;TMS offers a safe, non-invasive, and drug-free alternative, with no black box warning and no medication-related side effects. Clinical studies show that approximately 60% of patients achieve remission with TMS, making it a promising new treatment option for adolescents who have not found success with other treatments.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;During TMS Therapy, clinicians position a magnetic coil on the patient’s head to deliver targeted stimulation to specific brain regions involved in mood regulation. neurocare’s engineering team in Germany has developed advanced technology where the magnetic field is more efficient at providing the prescribed stimulation. This advancement improves the impact of treatment, giving patients the best possible chance to benefit from their psychiatrist’s prescribed therapy.&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt; 
&lt;p&gt;&lt;span&gt;“Our mission has always been to expand access to safe and effective treatments for those who need them most,” said Stanford Miller, Managing Director of neurocare group’s North American operations. “This clearance allows providers to offer adolescents a proven therapy without the risks and limitations of medication, giving hope to families searching for better treatment options.”&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;br&gt;&lt;/span&gt;&lt;span&gt;&amp;nbsp;&lt;br&gt;&lt;/span&gt;&lt;span&gt;Since 2021, neurocare has installed more than 300 Apollo systems in clinics and major institutions across the U.S., helping with the treatment of complex cases of Major Depressive Disorder (MDD) in adults, as well as Obsessive Compulsive Disorder (OCD). The Apollo TMS Therapy product line is FDA-cleared for the treatment of MDD in adult patients who have not had an adequate response to oral antidepressants. It is also FDA-cleared as an adjunctive treatment for OCD in adult patients who have not responded to traditional therapies. The same advanced technology is now FDA-cleared as an adjunctive treatment for adolescents with MDD. Most private and public insurers cover TMS Therapy for adults with MDD, and an increasing number are extending coverage to adolescents.&lt;/span&gt;&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=6673911&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fwww.neurocaregroup.com%2Fen-us%2Fnews-insights%2Fneurocare-groups-apollo-tms-therapy-devices-now-have-fda-clearance-to-treat-adolescents-suffering-with-major-depression&amp;amp;bu=https%253A%252F%252Fwww.neurocaregroup.com%252Fen-us%252Fnews-insights&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <category>Press Release</category>
      <category>Depression</category>
      <category>TMS</category>
      <category>FDA</category>
      <pubDate>Tue, 09 Sep 2025 22:30:00 GMT</pubDate>
      <guid>https://www.neurocaregroup.com/en-us/news-insights/neurocare-groups-apollo-tms-therapy-devices-now-have-fda-clearance-to-treat-adolescents-suffering-with-major-depression</guid>
      <dc:date>2025-09-09T22:30:00Z</dc:date>
      <dc:creator>neurocare group</dc:creator>
    </item>
    <item>
      <title>neurocare group receives FDA clearance for treatment of OCD with its Transcranial Magnetic Stimulation (TMS) devices</title>
      <link>https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-treatment-of-ocd-with-its-transcranial-magnetic-stimulation-tms-devices-1</link>
      <description>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-treatment-of-ocd-with-its-transcranial-magnetic-stimulation-tms-devices-1" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/Resources%20-%20Downloads%20-%20Sales/Apollo%20Images/neurocare-TMS2844_Patient-Clinician-ApolloTMS-Soleni%20(2).jpg" alt="neurocare group receives FDA clearance for treatment of OCD with its Transcranial Magnetic Stimulation (TMS) devices" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;span style="color: #000000;"&gt;Munich, Germany – August 20, 2025 &lt;/span&gt;- neurocare group AG (“neurocare” or the “Company”), a best practice platform for mental health and performance, today announced it has received FDA clearance for the treatment of Obsessive Compulsive Disorder (OCD) using its Apollo TMS Therapy devices, a state-of-the-art system in Transcranial Magnetic Stimulation.&lt;/p&gt; 
&lt;p&gt;OCD affects about 1.2% of U.S. adults in any given year, and approximately 2.3%—roughly one in 40 people—experience it at some point in their lifetime. Symptoms can include obsessive thoughts such as fears of contamination, harm, forbidden ideas, or need for symmetry, and compulsive behaviors like excessive cleaning, checking, arranging, mental rituals, or repeated reassurance seeking. These patterns can seriously impact the quality of a person’s daily life.&lt;/p&gt; 
&lt;p&gt;TMS Therapy is a non-invasive, evidence-based treatment modality already FDA cleared for patients with Major Depressive Disorder (MDD). For patients suffering from OCD, treatment options have been largely limited to cognitive behavioral therapy and medications like SSRIs, which often have modest success and high drop-out rates, with only about 30% of patients continuing with treatment long term. This new FDA clearance gives clinicians a much-needed tool, and a drug-free alternative for patients who have few effective treatment options.&lt;/p&gt; 
&lt;p&gt;TMS Therapy uses a strong magnetic field produced by a specialized coil which is placed on the head to stimulate targeted brain pathways. neurocare’s Apollo TMS Therapy systems support advanced treatment protocols that are well-suited for OCD treatment approaches, providing symptom relief for patients, thus enhancing the quality of life for this population.&lt;/p&gt; 
&lt;p&gt;“With this new FDA clearance, we can help more people living with OCD access a safe and effective, non-drug treatment option that can make a real difference in their daily lives. Our Apollo TMS Therapy technology sets a new standard of care in the treatment of OCD, empowering clinicians to deliver the highest level of patient care.” said Stanford Miller, Managing Director of neurocare group’s North American operations.&lt;/p&gt; 
&lt;p&gt;Since 2021, neurocare has installed more than 300 Apollo systems in clinics and large institutions across the U.S. which have been used to treat challenging cases of MDD. Apollo TMS Therapy is FDA-cleared for the treatment of MDD in patients who have had an inadequate response to oral antidepressants. The same technology is now also FDA-cleared for OCD. Most private and public insurers offer health benefits coverage for TMS Therapy for MDD, with some now offering coverage for OCD as well.&lt;/p&gt;</description>
      <content:encoded>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-treatment-of-ocd-with-its-transcranial-magnetic-stimulation-tms-devices-1" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/Resources%20-%20Downloads%20-%20Sales/Apollo%20Images/neurocare-TMS2844_Patient-Clinician-ApolloTMS-Soleni%20(2).jpg" alt="neurocare group receives FDA clearance for treatment of OCD with its Transcranial Magnetic Stimulation (TMS) devices" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;span style="color: #000000;"&gt;Munich, Germany – August 20, 2025 &lt;/span&gt;- neurocare group AG (“neurocare” or the “Company”), a best practice platform for mental health and performance, today announced it has received FDA clearance for the treatment of Obsessive Compulsive Disorder (OCD) using its Apollo TMS Therapy devices, a state-of-the-art system in Transcranial Magnetic Stimulation.&lt;/p&gt; 
&lt;p&gt;OCD affects about 1.2% of U.S. adults in any given year, and approximately 2.3%—roughly one in 40 people—experience it at some point in their lifetime. Symptoms can include obsessive thoughts such as fears of contamination, harm, forbidden ideas, or need for symmetry, and compulsive behaviors like excessive cleaning, checking, arranging, mental rituals, or repeated reassurance seeking. These patterns can seriously impact the quality of a person’s daily life.&lt;/p&gt; 
&lt;p&gt;TMS Therapy is a non-invasive, evidence-based treatment modality already FDA cleared for patients with Major Depressive Disorder (MDD). For patients suffering from OCD, treatment options have been largely limited to cognitive behavioral therapy and medications like SSRIs, which often have modest success and high drop-out rates, with only about 30% of patients continuing with treatment long term. This new FDA clearance gives clinicians a much-needed tool, and a drug-free alternative for patients who have few effective treatment options.&lt;/p&gt; 
&lt;p&gt;TMS Therapy uses a strong magnetic field produced by a specialized coil which is placed on the head to stimulate targeted brain pathways. neurocare’s Apollo TMS Therapy systems support advanced treatment protocols that are well-suited for OCD treatment approaches, providing symptom relief for patients, thus enhancing the quality of life for this population.&lt;/p&gt; 
&lt;p&gt;“With this new FDA clearance, we can help more people living with OCD access a safe and effective, non-drug treatment option that can make a real difference in their daily lives. Our Apollo TMS Therapy technology sets a new standard of care in the treatment of OCD, empowering clinicians to deliver the highest level of patient care.” said Stanford Miller, Managing Director of neurocare group’s North American operations.&lt;/p&gt; 
&lt;p&gt;Since 2021, neurocare has installed more than 300 Apollo systems in clinics and large institutions across the U.S. which have been used to treat challenging cases of MDD. Apollo TMS Therapy is FDA-cleared for the treatment of MDD in patients who have had an inadequate response to oral antidepressants. The same technology is now also FDA-cleared for OCD. Most private and public insurers offer health benefits coverage for TMS Therapy for MDD, with some now offering coverage for OCD as well.&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=6673911&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fwww.neurocaregroup.com%2Fen-us%2Fnews-insights%2Fneurocare-group-receives-fda-clearance-for-treatment-of-ocd-with-its-transcranial-magnetic-stimulation-tms-devices-1&amp;amp;bu=https%253A%252F%252Fwww.neurocaregroup.com%252Fen-us%252Fnews-insights&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <category>Press Release</category>
      <category>TMS</category>
      <category>FDA</category>
      <category>OCD</category>
      <pubDate>Wed, 20 Aug 2025 22:30:00 GMT</pubDate>
      <guid>https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-treatment-of-ocd-with-its-transcranial-magnetic-stimulation-tms-devices-1</guid>
      <dc:date>2025-08-20T22:30:00Z</dc:date>
      <dc:creator>neurocare group</dc:creator>
    </item>
    <item>
      <title>neurocare group Receives FDA Clearance for Its Industry-Leading iTBS Protocol for TMS</title>
      <link>https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-its-industry-leading-itbs-protocol-for-tms-1</link>
      <description>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-its-industry-leading-itbs-protocol-for-tms-1" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/neurocare-apollo-tms-and-soleni-patient-comfort-chair.jpg" alt="neurocare group Receives FDA Clearance for Its Industry-Leading iTBS Protocol for TMS" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;Atlanta, Georgia, August 22 2024 - neurocare group&amp;nbsp; (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance &lt;span&gt;is pleased to announce that it has received FDA clearance for its industry-leading intermittent Theta Burst Stimulation (iTBS) protocol, available across its Apollo TMS Therapy System and other Transcranial Magnetic Stimulation systems for clinical practice.&amp;nbsp;&lt;/span&gt;&lt;/p&gt;</description>
      <content:encoded>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-its-industry-leading-itbs-protocol-for-tms-1" title="" class="hs-featured-image-link"&gt; &lt;img src="https://www.neurocaregroup.com/hubfs/neurocare-apollo-tms-and-soleni-patient-comfort-chair.jpg" alt="neurocare group Receives FDA Clearance for Its Industry-Leading iTBS Protocol for TMS" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;Atlanta, Georgia, August 22 2024 - neurocare group&amp;nbsp; (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance &lt;span&gt;is pleased to announce that it has received FDA clearance for its industry-leading intermittent Theta Burst Stimulation (iTBS) protocol, available across its Apollo TMS Therapy System and other Transcranial Magnetic Stimulation systems for clinical practice.&amp;nbsp;&lt;/span&gt;&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=6673911&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fwww.neurocaregroup.com%2Fen-us%2Fnews-insights%2Fneurocare-group-receives-fda-clearance-for-its-industry-leading-itbs-protocol-for-tms-1&amp;amp;bu=https%253A%252F%252Fwww.neurocaregroup.com%252Fen-us%252Fnews-insights&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <category>Press Release</category>
      <category>Depression</category>
      <category>TMS</category>
      <category>FDA</category>
      <pubDate>Wed, 21 Aug 2024 22:30:00 GMT</pubDate>
      <guid>https://www.neurocaregroup.com/en-us/news-insights/neurocare-group-receives-fda-clearance-for-its-industry-leading-itbs-protocol-for-tms-1</guid>
      <dc:date>2024-08-21T22:30:00Z</dc:date>
      <dc:creator>neurocare group</dc:creator>
    </item>
  </channel>
</rss>
